[breadcrumb_custom]

Uncovering the Potential of Aclaris Therapeutics Inc (ACRS) Stock

In terms of market performance, Aclaris Therapeutics Inc had a somewhat inconsistent run in. The highest value for the stock in the past year was $14.53 on 02/13/23, while the lowest value was $0.59 on 11/13/23.

52-week price history of ACRS Stock

Analyzing the 52-week price history of a stock, including its high and low prices, can provide valuable insight into its current status and potential future performance. Aclaris Therapeutics Inc’s current trading price is -92.70% away from its 52-week high, while its distance from the 52-week low is 79.60%. The stock’s price range for this period has remained between $0.59 and $14.53. The Healthcare sector company’s shares managed to surpass a trading volume of around 5.19 million for the day, which was noticeably higher compared to the shares’ average daily volume of 5.07 million over the last three months.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Financial Performance and Market Capitalization

Aclaris Therapeutics Inc (ACRS) has experienced a quarterly decline of -80.66% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 75.09M and boasts a workforce of 105 employees.

Moving average and trading volume data

Based on Barchart.com data, the company’s moving average over the 100-day period was 2.9825, with a change in price of -6.9400. Similarly, Aclaris Therapeutics Inc recorded 3,604,817 in trading volume during the last 100 days, posting a change of -86.75%.

ACRS Debt-to-equity ratio analysis

The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for ACRS stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.01.

ACRS Stock Stochastic Average

As of today, the raw stochastic average of Aclaris Therapeutics Inc over the past 50 days is 52.73%. This is a increase compared to the raw stochastic average of the last 20 days, which was recorded at 44.03%. Additionally, the Stochastic %K and %D values for the company were 56.23% and 64.84%, respectively, over the past 20 days.

ACRS Stock Price Performance Analysis

The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. Until today this year the stock’s price performance recorded an increase of 0.95%. However, over the last six months, the performance has been stronger by -87.76%. The price of ACRS decreased -10.17% over the last 30 days. And in the last five days, it has fallen by -8.62%.

Leave a Reply

Your email address will not be published. Required fields are marked *

On Key

Related Posts